Clinical Trial Update: A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase II study investigating carelizumab with irinotecan and apatinib as second-line therapy for advanced gastric cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Carelizumab
• Irinotecan (Irinotecan)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN